Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of In Vivo Deprenyl-Derivedl-Methamphetamine

William P. Melega, Arthur K. Cho, Debra Schmitz, Ronald Kuczenski and David S. Segal
Journal of Pharmacology and Experimental Therapeutics February 1999, 288 (2) 752-758;
William P. Melega
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur K. Cho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debra Schmitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Kuczenski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Segal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This study evaluated whether the caudate-putamen dopamine response that has been observed after deprenyl administration could be attributed exclusively to metabolically generated l-methamphetamine (l-MeAmp). Brain and plasma levels of deprenyl andl-MeAmp were measured after deprenyl (10 mg/kg s.c.) from 10 to 60 min in conscious rats. Peak caudate-putamen levels were observed for deprenyl (15 nmol/g) at 10 min and forl-MeAmp (3 nmol/g) at 30 min. In a parallel study,l-MeAmp metabolism was evaluated. Afterl-MeAmp (20 mg/kg s.c.), metabolite levels remained low relative to those of the parent compound: l-amphetamine, ∼5 to 12%; andpara-hydroxy-l-methamphetamine (OH-MeAmp), ∼0.25%. Accordingly, l-MeAmp was considered to be the primary pharmacologically active deprenyl metabolite. A pharmacokinetic-pharmacodynamic analysis was then used to relate these pharmacokinetic data to the results of previous microdialysis studies in which increases in extracellular dopamine were measured in the caudate-putamen after l-MeAmp (3–18 mg/kg) and after deprenyl (10 mg/kg). Dopamine response-area under curve versus dose plots were generated and used to show that an administered dose of 4 mg/kg l-MeAmp would be necessary to effect a dopamine response-area under curve comparable to that observed after the deprenyl dose. However, the present pharmacokinetic results indicated that l-MeAmp brain levels after deprenyl corresponded to those that would be obtained from 0.4 mg/kgl-MeAmp (i.e., one tenth of the required dose). Collectively, these results suggest that the acute increases in extracellular dopamine observed after deprenyl are not due uniquely to metabolically generated l-MeAmp but also to other actions of deprenyl at the dopamine terminal.

Footnotes

  • Send reprint requests to: William P. Melega, Ph.D., Department of Molecular and Medical Pharmacology, 23-120 CHS, UCLA School of Medicine, Box 951735, Los Angeles, CA 90095-1735. E-mail:wmelega{at}mednet.ucla.edu

  • ↵1 This work was supported in part by U.S. Department of Energy Grant DE-FC03–87ER60615 and Intra-agency Agreement 1-YO1-DA500038-00.

  • Abbreviations:
    d-Amp
    d-amphetamine
    d-MeAmp
    d-methamphetamine
    l-MeAmp
    l-methamphetamine
    MAO
    monoamine oxidase
    DA
    dopamine
    DOPAC
    3,4-dihydroxyphenylacetic acid
    HVA
    homovanillic acid
    5-HIAA
    5-hydroxyindoleacetic acid
    OH-MeAmp
    para-hydroxymethamphetamine
    HPLC
    high-pressure liquid chromatography
    GC/MS
    gas chromatography-mass spectrometry
    AUC
    area under the curve
    • Received May 26, 1998.
    • Accepted September 4, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 288 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 288, Issue 2
1 Feb 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of In Vivo Deprenyl-Derivedl-Methamphetamine
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of In Vivo Deprenyl-Derivedl-Methamphetamine

William P. Melega, Arthur K. Cho, Debra Schmitz, Ronald Kuczenski and David S. Segal
Journal of Pharmacology and Experimental Therapeutics February 1, 1999, 288 (2) 752-758;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of In Vivo Deprenyl-Derivedl-Methamphetamine

William P. Melega, Arthur K. Cho, Debra Schmitz, Ronald Kuczenski and David S. Segal
Journal of Pharmacology and Experimental Therapeutics February 1, 1999, 288 (2) 752-758;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Evidence That Melanocortin 4 Receptor Mediates Hemorrhagic Shock Reversal Caused by Melanocortin Peptides
  • Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals?
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics